Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L. reuteri-IL-22
- Development stage
- Preclinical
- Lead developer
- ChromoLogic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
L. reuteri-IL-22 is a genetically engineered live biotherapeutic product (LBP) developed by ChromoLogic. It utilizes the probiotic bacterium *Limosilactobacillus reuteri* as a delivery vehicle to express or deliver Interleukin-22 (IL-22). The asset is currently in preclinical development, primarily targeting ovarian cancer. By leveraging the natural properties of the probiotic, the therapy aims to modulate the tumor microenvironment or provide localized cytokine delivery to enhance therapeutic efficacy in solid tumors. The program is part of ChromoLogic's broader drug delivery platform focused on engineered microbes for localized therapeutic protein production.
- Other names
- IL-22 probioticIL22 probioticIL 22 probioticgenetically engineered Limosilactobacillus reuteri
02
Targets
IL-22R (Interleukin 22 Receptor)
Beyond the preview
Go deeper on L. reuteri-IL-22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L. reuteri-IL-22.